AngioDynamics, Inc. (NASDAQ:ANGO) Receives $19.50 Consensus Price Target from Brokerages

AngioDynamics, Inc. (NASDAQ:ANGO) has earned a consensus recommendation of “Hold” from the five brokerages that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $19.50.

A number of analysts recently issued reports on ANGO shares. Canaccord Genuity Group increased their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. HC Wainwright lifted their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Zacks Research downgraded shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Finally, Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd.

Insiders Place Their Bets

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares of the company’s stock, valued at $953,046.40. This represents a 26.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 6.00% of the stock is currently owned by insiders.

Institutional Trading of AngioDynamics

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of AngioDynamics in the second quarter valued at $49,480,000. Weber Capital Management LLC ADV purchased a new position in shares of AngioDynamics during the second quarter valued at $17,649,392. Paradigm Capital Management Inc. NY acquired a new position in AngioDynamics during the second quarter valued at $8,732,000. Western Standard LLC acquired a new position in AngioDynamics during the second quarter valued at $5,037,000. Finally, Bank of America Corp DE lifted its stake in AngioDynamics by 262.7% in the 1st quarter. Bank of America Corp DE now owns 503,640 shares of the medical instruments supplier’s stock worth $5,726,000 after acquiring an additional 364,763 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Stock Up 1.6%

Shares of ANGO stock opened at $15.67 on Friday. AngioDynamics has a fifty-two week low of $9.39 and a fifty-two week high of $16.29. The stock has a market cap of $647.64 million, a P/E ratio of -18.01 and a beta of 0.33. The business has a fifty day simple moving average of $15.19 and a 200-day simple moving average of $12.76.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, sell-side analysts anticipate that AngioDynamics will post -0.25 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc (NASDAQ: ANGO) is a medical technology company that develops and manufactures minimally invasive devices used in vascular, oncology, and surgical procedures. Its products are designed to help physicians diagnose and treat vascular disease, remove or manage blood clots, and deliver targeted therapies for certain cancers and other conditions.

The company’s product portfolio includes the Auryon Atherectomy System for treating peripheral arterial disease, the AngioVac System for the removal of unwanted intravascular material, and the NanoKnife System, which uses irreversible electroporation to ablate soft-tissue tumors.